University Institute of Cardiology and Pneumology of Quebec, University Laval
Marc Fortin
In this monocentric randomized controlled trial, 120 potential non small cell lung cancer (NSCLC) patients for which tissue diagnosis and material for next generation sequencing (NGS) is required for clinical management will be approached the day of their endobronchial ultrasound to participate in the study. They will be randomized to 2 vs 3 passes/lymph node and will all undergo liquid biopsy. The co-primary outcomes are 1)the rate of obtention of adequate material for NGS testing with 2 vs 3 passes/lymph node and 2)the percentage of patients for which liquid biopsy allows to identify clinically pertinent findings not available from tissue biopsy
Lung Cancer
Non Small Cell Lung Cancer
Circulating Tumor Cell
Endobronchial ultrasound
Not Applicable
| Study Type : | Interventional |
| Estimated Enrollment : | 120 participants |
| Masking : | Single |
| Masking Description : | Pathologist will be blinded to study arm when analyzing samples |
| Primary Purpose : | Diagnostic |
| Official Title : | OPTimizing Endobronchial Ultrasound Sampling In Suspected Non Small Cell Lung Cancer for Molecular Markers : A Pragmatic Randomized Controlled TriaL |
| Actual Study Start Date : | November 1, 2022 |
| Estimated Primary Completion Date : | November 1, 2024 |
| Estimated Study Completion Date : | February 1, 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 2 passes per target on EBUS |
Procedure: Endobronchial ultrasound |
|
Experimental: 3 passes per target on EBUS |
Procedure: Endobronchial ultrasound |
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.